ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

• July 1, 2026

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

• July 1, 2026

• 1 min

Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study

• by Tao Zhang, Xue Li, Junsong Zeng, Maosen Xu, Yan Tie

• June 30, 2026

Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis

• by Claire Palles, Luke Freeman-Mills, Edward Arbe-Barnes, Nathalie Feeley, Laura Chegwidden, Helen Curley, Sara Galavotti, Connor Woolley, Jeremy Cheadle, Dmitri Mouradov, Oliver Sieber, Silvia Salatino, Steve Thorn, Anshita Goel, Juan Fernandez-Tajes, Sulochana Omwenga, Sujata Biswas, Timothy Maughan, Simon J Leedham, S:CORT Consortium, UK Colorectal Cancer Genomics Consortium, CORGI Consortium, WGS500 Consortium, Viktor Hendrik Koelzer, Lai Mun Wang, Roland Arnold, James Edward East, Ian Tomlinson

• July 1, 2026